EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Amikacin
CLASS
Aminoglycoside
TARGET PROTEIN
formyl-methionyl-tRNA
MECHANISM OF ACTION
Bactericidal activity (It is a protein synthesis inhibitor that hinders binding of formyl-methionyl-tRNA to the bacterial ribosomal 30S subunit)
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Experimental
MODE OF ADMINISTRATION
Injectable
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32091697/
https://pubmed.ncbi.nlm.nih.gov/14659652/
SIMILAR TARGETS IN OTHER SPECIES
30S ribosomal protein S12 ~ Escherichia coli (strain K12)
DRUG BANK ID
DB00479
EXTERNAL LINKS
Human Metabolome Database HMDB0014622
KEGG Drug D02543
KEGG Compound C06820
PubChem Compound 37768
PubChem Substance 46506386
ChemSpider 34635
BindingDB 50237603
RxNav 641
ChEBI 2637
ChEMBL CHEMBL177
ZINC ZINC000008214483
Drugs.com Drugs.com Drug Page https://www.drugs.com/cdi/amikacin.html
Wikipedia Amikacin
REFERENCE
Wu, A., March, L., Zheng, X., Huang, J., Wang, X., Zhao, J., M.Blyth, F., Smith, E., Buchbinder, R., & Hoy, D. (2020). Enhanced Reader.pdf. In Nature (Vol. 388, pp. 1–14).Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4